Treatment with bevacizumab, a humanized monoclonal antibody that specifically neutralizes VEGF-A, has been documented to lead to hearing improvement or tumor shrinkage in 30–60% of NF2 patients and is approved for NF2 treatment in the United Kingdom [18]. The gene discussed is NF2; the disease is neoplasm.